An article from
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
Published June 11, 2026
By
BioPharma Dive staff
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
TL;DRAI
J&J's Imaavy advanced for autoimmune hemolytic anemia; Beren Therapeutics secured $300M for Niemann-Pick disease therapy—rare-disease market remains well-funded. Orphan-drug unmet-need positioning and tax incentives drive sustained investor confidence; biotech slowdown hasn't dampened capital flow to premium-priced specialty therapies.
653 words~3 min read
